Biologics News

An autologous dermal fibroblast injection into the bone-tendon interface after arthroscopic rotator cuff repair may promote tissue healing and reduce the rate of retears, according to published results.

KOLOA, Hawaii — In this video, Aaron J. Krych, MD, highlights key discussions held during a session on meniscus tears and treatment at Orthopedics Today Hawaii.

Published results showed the use of a novel bioresorbable scaffold-anchor to augment healing after rotator cuff repair may not yield clinically superior outcomes compared with a standard anchor.

Healio highlights the most-read research, topics and news in orthobiologics in 2024.

The FDA approved Symvess as a vascular conduit for extremity arterial injuries in adults when urgent revascularization is needed to avoid limb loss, and an autologous vein graft is not feasible, according to a press release.

Percutaneous orthobiologic treatment may be an effective alternative to home exercise therapy for treatment of rotator cuff tears, according to results published in BMC Musculoskeletal Disorders.

Acuitive Technologies Inc. announced FDA 510(k) clearance for Citrepore, a synthetic bioactive bone void filler designed to promote bone healing after orthopedic surgical procedures, according to a company press release.

Published results showed positive long-term clinical and functional outcomes for patients with knee chondral defects who underwent one-step cartilage repair with a hyaluronic acid-based scaffold and bone marrow aspirate concentrate graft.

The American Academy of Orthopaedic Surgeons Registry Program released its 2024 Shoulder & Elbow Registry annual report, according to a press release.